ID   MCF-7R
AC   CVCL_Y493
SY   MCF7R
DR   cancercelllines; CVCL_Y493
DR   ChEMBL-Cells; CHEMBL3307593
DR   ChEMBL-Targets; CHEMBL614327
DR   PubChem_Cell_line; CVCL_Y493
DR   Wikidata; Q54904409
RX   PubMed=17671737;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=17671737; DOI=10.3892/ijmm.20.3.329;
RA   Poma P., Notarbartolo M., Labbozzetta M., Maurici A., Carina V.,
RA   Alaimo A., Rizzi M., Simoni D., D'Alessandro N.;
RT   "The antitumor activities of curcumin and of its isoxazole analogue
RT   are not affected by multiple gene expression changes in an MDR model
RT   of the MCF-7 breast cancer cell line: analysis of the possible
RT   molecular basis.";
RL   Int. J. Mol. Med. 20:329-335(2007).
//